Business Standard

Vista Pharmaceuticals Share Price

Know More

13.90 0.05 (0.36%)

12:00 AM,14th Jun 2024
Stock not traded

BSE : 524711


Sector : Health care

ISIN Code : INE427C01021

  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: 14-Jun-2024 | 12:00 AM IST

Market Cap (₹ Cr)


Turnover (₹ Cr)


Volume (Shares)


Face Value


52-WK High


52-WK High Date


52-WK Low


52-WK Low Date


All Time High


All Time High Date


All Time Low


All Time Low Date


Vista Pharmaceuticals Ltd

Vista Pharmaceuticals Limited was incorporated on January 251991 with the Registrar of Companies Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7 1991. The Company is engaged in the formulation of pharmaceutical products. It offers a range of products mainly into the therapeutic areas of gastrointestinal pain management and anti-infection catering to common ailments. This division is a primary contributor to the domestic sales of Torrent Pharmaceuticals Ltd. based in Hyderabad India.The Company was in process of setting up a 100% EOU for manufacture of drug formulations with an installed capacity of 400 million tablets & 200 million capsules per annum. Apar...
Read More

Vista Pharma. Announcement

<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>VISTA PHARMACEUTICALS LTD.</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24239TG1991PLC012264</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2023-2024</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>FY 2023-24 2024-25</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>FY 2023-24 2022-23</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Barkha Jain</td></tr><tr><td>Designation :-</td><td>Company Secretary </td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Suneel Pachipala</td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 30/04/2024<br/><br/></div>

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>VISTA PHARMACEUTICALS LTD.</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24239TG1991PLC012264</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Bharka Jain <br/> Designation: Company Secretary <br/> EmailId:</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: suneel Pachipala <br/> Designation: Chief Financial Officer <br/> EmailId:</div> </div> <div> <br/> Date: 30/04/2024<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

View More

Vista Pharmaceuticals Ltd - Key Fundamentals

Market Cap (₹ Cr)


EPS - TTM (₹) [S]


P/E Ratio (X) [S]


Face Value (₹) 2
Latest Dividend (%)-
Latest Dividend Date -
Dividend Yield (%) -
Book Value Share (₹) [S]9.99
P/B Ratio (₹) [S]1.39

Funds Owning this Stock

Scheme Name Amount Invested (₹ Cr) No Of Shares Net Asset (%)

Research Reports

Date Broker Action Prices(₹) Report
Data Not Found

Stock Strength

Today's Low/High



Week Low/High



Month Low/High



Year Low/High



All time Low/High



Share Price Returns

1 Week0.00%%0.390.75%
1 Month-2.80%%5.325.62%
3 Month5.62%%5.335.96%
6 Month-11.18%%9.1910.78%
1 Year31.26%%21.7725.11%
3 Year15.54%%46.5148.41%

Company Info

Company Information

Chairman & Wholetime Director : Dhananjaya Alli

Non-Exec. & Independent Dir. : G Narendra

Non-Exec & Non-Independent Dir : M H Rao

Non-Exec & Non-Independent Dir : Stanley Prabhakar Reddy

Non-Exec. & Independent Dir. : Umesh V Banakar

Non-Exec. & Independent Dir. : Chakravarthula Divya Bhavani

Director : Umakanth Katta

Director : Divakar Reddy Yerrabommanahalli

Managing Director : Murali Meraga

Whole Time Director (Operatio : Pavan Sathvik Gilaka

Company Sec. & Compli. Officer : Barkha Jain

Registered Office: Plot No 10to14 16to20 APIIC, Industrial Estate Chotyal,Nalgonda,Telangana- Ph: 91-09291015956


FAQs about Vista Pharmaceuticals Ltd

1. What's the Vista Pharmaceuticals Ltd share price today?
Vista Pharmaceuticals Ltd share price was Rs 13.90 at close on 14th Jun 2024. Vista Pharmaceuticals Ltd share price was up by 0.36% over the previous closing price of Rs 13.85. Vista Pharmaceuticals Ltd share price trend:

  • Last 1 Month: Vista Pharmaceuticals Ltd share price moved down by 2.80% on BSE
  • Last 3 Months: Vista Pharmaceuticals Ltd share price moved up by 5.62% on BSE
  • Last 12 Months: Vista Pharmaceuticals Ltd share price moved up by 31.26% on BSE
  • Last 3 Years: Vista Pharmaceuticals Ltd price moved up by 15.54% on BSE

2. How can I quickly analyse the performance of the Vista Pharmaceuticals Ltd stock?
The performance of the Vista Pharmaceuticals Ltd stock can be quickly analysed on the following metrics:

  • The stock's PE is _
  • Price to book value ratio is 1.39
  • Dividend yield of 0.00
  • The EPS (trailing 12 months) of the Vista Pharmaceuticals Ltd stock is Rs 0.00

3. What is the market cap of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has a market capitalisation of Rs 54 crore.

4. What is Vista Pharmaceuticals Ltd's 52-week high/low share price?
The Vista Pharmaceuticals Ltd’s 52-week high share price is Rs 19.70 and 52-week low share price is Rs 8.12.

5. Is the Vista Pharmaceuticals Ltd profitable?
On a consolidated basis, Vista Pharmaceuticals Ltd reported a profit of Rs 0.09 crore on a total income of Rs 3.23 crore for the quarter ended 2024. For the year ended Mar 2024, Vista Pharmaceuticals Ltd had posted a profit of Rs 0.09 crore on a total income of Rs 3.23 crore.

6. Which are Vista Pharmaceuticals Ltd’s peers in the Health care sector?
Vista Pharmaceuticals Ltd’s top 5 peers in the Health care sector are Vivo Bio Tech, Sandu Pharma., Vineet Laborator, Vista Pharma., Shree Ganesh Bio, Roopa Industries, Veerhealth Care.

7. Who owns how much in Vista Pharmaceuticals Ltd?
Key changes to the Vista Pharmaceuticals Ltd shareholding are as follows:

  • Promoter holding in Vista Pharmaceuticals Ltd has gone down to 27.81 per cent as of Mar 2024 from 30.49 per cent as of Jun 2023.